AstraZeneca and Merck’s LYNPARZA® (olaparib) Approved in Japan as First-Line Maintenance Therapy in Patients with BRCA-Mutated Advanced Ovarian Cancer

Off Science and Research

Dateline City:
KENILWORTH, N.J.

LYNPARZA is the Only PARP Inhibitor Approved in Japan

KENILWORTH, N.J.–(BUSINESS WIRE)–AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United
States and Canada, today announced that Japan’s Pharmaceuticals and
Medical Devices Agency (PMDA) has approved LYNPARZA as a maintenance
treatment after first-line chemotherapy in patients with BRCA-mutated
(BRCAm) ovarian cancer.

Language:
English

Contact:

Media Contacts:

Pamela Eisele
(267) 305-3558

Michael Close
(267) 305-1211

Investor Contacts:

Teri Loxam
(908) 740-1986

Michael DeCarbo
(908) 740-1807

Ticker Slug:
Ticker:
MRK

Exchange:
NYSE

@Merck

read more

Read Original Article: AstraZeneca and Merck’s LYNPARZA® (olaparib) Approved in Japan as First-Line Maintenance Therapy in Patients with BRCA-Mutated Advanced Ovarian Cancer »

About The Author